ReviewAntioxidants (Basel, Switzerland)2026
Antioxidant Strategies in Testicular Ischemia-Reperfusion Injury-Translational Insights and Clinical Implications for Testicular Torsion Management.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Testicular torsion is a time-critical urological emergency in which surgical detorsion, the only accepted treatment, simultaneously rescues and injures the gonad. Restoration of blood flow triggers a burst of reactive oxygen and nitrogen species, neutrophil recruitment, inflammasome activation, and regulated germ cell death, so that a substantial proportion of anatomically salvaged testes still undergo atrophy and functional loss. A large experimental literature, running to several hundred reports, has shown that antioxidants of almost every chemical class attenuate this injury in rodent models, yet no antioxidant has entered routine clinical use as an adjunct to detorsion in humans, and we are not aware of any adequately powered randomized trial in this setting. This narrative review integrates the redox pathophysiology of testicular ischemia-reperfusion injury with an appraisal of the agents tested against it, and then asks why the translational gap has proved so durable. We examine model heterogeneity, the dominance of pretreatment designs that cannot be reproduced in an emergency department, the reliance on short-term surrogate biochemistry rather than fertility endpoints, and the sobering precedents of neuroprotection and cardioprotection. We close with a roadmap for first-in-human evaluation, covering candidate prioritization, route and timing of administration, biomarker selection, and a feasible trial architecture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.